Head and Neck Carcinoma Clinical Trial
Official title:
HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers
This clinical trial tests whether intensity modulated proton therapy after surgery works to shrink tumors in patients with head and neck cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.
Status | Recruiting |
Enrollment | 117 |
Est. completion date | November 15, 2026 |
Est. primary completion date | November 15, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >= 18 years - Histological confirmation of a newly diagnosed non-human papillomavirus (HPV) associated malignant epithelial cancer in the head and/or neck. Diagnosis requires confirmation of p16 and/or HPV DNA negativity for oropharyngeal and unknown primary sites. p16 positivity in skin cancers is allowed - Primary lesion located in the nasal cavity, paranasal sinuses, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, lymph nodes (unknown primary or metastasis from head and neck [HN]-skin primary) or skin cancer where lymph node radiation is recommended - NOTE: Patients with primary lesions in the larynx must have a T3 primary, bulky T2 primary (> 6 cc), and/or at least 1 regional lymph node - Confirmation of American Joint Committee on Cancer (AJCC) 8th edition defined M0 established by positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) - Eastern Cooperative Oncology Group (ECOG) performance status (0-1 prior to initial treatment) - Able to provide written informed consent - Able to complete questionnaires independently or with assistance - Willing to return to enrolling institution for follow up during the observation phase - Hemoglobin >= 8.0 g/dl (within 8 weeks of registration) - Platelets >= 75,000 cells/mm^3 (within 8 weeks of registration) - Absolute neutrophil count > 1500 cells/mm^3 (within 8 weeks of registration) - Coronavirus disease 2019 (Covid-19) testing per institutional standard. If pre-treatment testing, patients should be negative prior to starting treatment or symptom free for at least 14 days from documented positive test. Vaccination status should be documented Exclusion Criteria: - Pregnant women (serum pregnancy test required before treatment per department policy) - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy - NOTE: Patients known to be HIV positive, but without clinical evidence of immunocompromised state, are eligible for this trial - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm - Other active malignancy =< 2 years prior to registration - EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix and prostate cancer with a Gleason score of 6 or less - NOTE: If there is a history or prior malignancy, they must not be receiving ongoing anticancer treatment - History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias - Prior radiation therapy that would have a clinically significant overlap with the intended head/neck radiation - Unable to receive proton therapy because of extensive metallic hardware in close proximity to treatment site, logistical circumstances, or any other reason - Any of the following diagnoses: HPV-associated squamous cell carcinoma, germ cell tumors, hematologic malignancies, neuroendocrine malignancies, adenoid cystic carcinoma, sarcomas of bone, benign tumors |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic Hospital in Arizona | Phoenix | Arizona |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of local/regional control (LRF) | The 2-year LRF rate will be estimated by counting the number of patients with a local or regional failure and dividing by the total number of eligible patients. | At 2 years | |
Secondary | Incidence of acute adverse events | The maximum grade for each type of acute adverse event will be recorded for each patient. Data will be summarized as frequencies and relative frequencies. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. | Up to 3 months after radiation therapy | |
Secondary | Incidence of late adverse events | The maximum grade for each type of late adverse event will be recorded for each patient. Data will be summarized as frequencies and relative frequencies. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. | Up to 3 years after completion of radiation therapy | |
Secondary | Incidence of secondary acute effects attributable to radiation therapy | The electronic health record will be reviewed for treatments related to secondary acute effects such as PEG tube placement, duration and dose of narcotic analgesia required, weight loss, and hospitalization days. | Up to 3 months after completion of radiation therapy | |
Secondary | Quality of life (QOL) and financial burden - MDADI | MD Anderson Dysphagia Inventory (MDADI) will be utilized to assess patient reported quality-of-life and financial burden. Changes from baseline to end of therapy as well as repeated measures mixed models will be utilized to assess effect of treatment. The QOL measurements will be summarized at each time point as mean +/- standard deviation and median (minimum value, maximum value). Changes in the QOL measurements from baseline will be determined at each follow-up measurement. These will be displayed as spaghetti plots. The assessment of the changes at each time point will be done with a paired t-test or Wilcoxon signed rank test, whichever is appropriate. Scale of 0 being least and 10 being greatest effect. | Up to 10 years | |
Secondary | Quality of life (QOL) and financial burden - EQ-5D-5L | European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L) will be utilized to assess patient reported quality-of-life and financial burden. Changes from baseline to end of therapy as well as repeated measures mixed models will be utilized to assess effect of treatment. The QOL measurements will be summarized at each time point as mean +/- standard deviation and median (minimum value, maximum value). Changes in the QOL measurements from baseline will be determined at each follow-up measurement. These will be displayed as spaghetti plots. The assessment of the changes at each time point will be done with a paired t-test or Wilcoxon signed rank test, whichever is appropriate. Scale of 0 being least and 10 being greatest effect. | Up to 10 years | |
Secondary | Quality of life (QOL) and financial burden - OMWQ-HN | Oral Mucositis Weekly Questionnaire (OMWQ-HN) will be utilized to assess patient reported quality-of-life and financial burden. Changes from baseline to end of therapy as well as repeated measures mixed models will be utilized to assess effect of treatment. The QOL measurements will be summarized at each time point as mean +/- standard deviation and median (minimum value, maximum value). Changes in the QOL measurements from baseline will be determined at each follow-up measurement. These will be displayed as spaghetti plots. The assessment of the changes at each time point will be done with a paired t-test or Wilcoxon signed rank test, whichever is appropriate. Scale of 0 being least and 10 being greatest effect. | Up to 10 years | |
Secondary | Regional recurrence rates | The regional head and neck cancer recurrence cumulative incidence will be estimated using a competing risks method (Gooley et al.). The competing risks will be local/distant head and neck cancer recurrence and death. | Up to 10 years | |
Secondary | Local recurrence incidence | The local head and neck cancer recurrence cumulative incidence will be estimated using a competing risks method (Gooley et al.). The competing risks will be regional/distant head and neck cancer recurrence and death. | Up to 10 years | |
Secondary | Distant recurrence rates | The distant head and neck cancer recurrence cumulative incidence will be estimated using a competing risks method (Gooley et al.). The competing risks will be local/regional head and neck cancer recurrence and death. | Up to 10 years | |
Secondary | Invasive disease-free survival (DFS) | The DFS will be estimated with a Kaplan-Meier estimator and curve. Estimates will be given for specific time points along with 95% confidence intervals. | From registration until the time of disease recurrence or death due to any cause, assessed up to 10 years | |
Secondary | Overall survival (OS) | The OS will be estimated with a Kaplan-Meier estimator and curve. Estimates will be given for specific time points along with 95% confidence intervals. | From registration to death due to any cause, assessed up to 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04110249 -
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03663985 -
FALCOn (Facteur AnthropoLogique Cancer Orl)
|
||
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05077072 -
Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04151082 -
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
|
Phase 1/Phase 2 | |
Completed |
NCT03964896 -
Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT02474095 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
|
N/A | |
Withdrawn |
NCT03261180 -
Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer
|
N/A | |
Terminated |
NCT04618432 -
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
|
||
Active, not recruiting |
NCT02615275 -
Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy
|
N/A | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
Recruiting |
NCT04870762 -
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
|
Phase 2 | |
Completed |
NCT02369835 -
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
|
Phase 3 | |
Completed |
NCT03902535 -
Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
|
||
Recruiting |
NCT05526924 -
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT03795610 -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
|
Phase 2 |